{
    "organizations": [],
    "uuid": "71b84dda176addaf80813d81d1b3b5c02136356f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sorrentos-and-yuhans-joint-venture/brief-sorrentos-and-yuhans-joint-venture-immuneoncia-receives-approval-idUSASB0C3XB",
    "ord_in_thread": 0,
    "title": "BRIEF-Sorrento's And Yuhan's Joint Venture, Immuneoncia, Receives Approval",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 5 (Reuters) - Sorrento Therapeutics Inc:\n* SORRENTO‘S AND YUHAN‘S JOINT VENTURE, IMMUNEONCIA, RECEIVES APPROVAL TO BEGIN CLINICAL TRIAL OF ANTI-PD-L1 MONOCLONAL ANTIBODY IN SOUTH KOREA\n* SORRENTO - SOUTH KOREAN MINISTRY FOR FOOD AND DRUG SAFETY HAS APPROVED IMMUNEONCIA THERAPEUTICS’ IND FOR INITIATION OF CLINICAL TRIALS FOR STI-A1015 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-05T21:24:00.000+02:00",
    "crawled": "2018-02-06T23:59:07.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "sorrento",
        "therapeutic",
        "inc",
        "sorrento",
        "yuhan",
        "joint",
        "venture",
        "immuneoncia",
        "receives",
        "approval",
        "begin",
        "clinical",
        "trial",
        "monoclonal",
        "antibody",
        "south",
        "korea",
        "sorrento",
        "south",
        "korean",
        "ministry",
        "food",
        "drug",
        "safety",
        "approved",
        "immuneoncia",
        "therapeutic",
        "ind",
        "initiation",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}